ARCHIVES

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

This article is from The Cancer Letter archive.

Vol. 35 No. 5 | May 25, 2012

Download PDF Visit The Full Archive

Related Articles

GA Draft Report Lukewarm On Cancer Survival Improvement; NCI Says It Is “Opinion, Not Fact”

April 3, 1987

NSABP Researcher Committed Misconduct, NIH Investigation Finds

March 18, 1994

NCAB Discussion Of Working Group Report

February 28, 2003

Age Shouldn’t Determine Lung Cancer Treatment, ASCO Says In New Guideline

November 27, 2009

BSA, BSC Approve Concept for NCI Scholars Program

March 7, 1997

FDA Grants Accelerated Approval to Imbruvica

November 29, 2013